Carlsmed (NASDAQ:CARL) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Carlsmed (NASDAQ:CARL) from a sell rating to a hold rating in a report issued on Saturday.

Several other equities research analysts also recently weighed in on CARL. Weiss Ratings began coverage on shares of Carlsmed in a research report on Thursday, October 16th. They issued a “sell (e)” rating for the company. Truist Financial reiterated a “buy” rating and issued a $20.00 price target (up from $18.00) on shares of Carlsmed in a research note on Friday, November 7th. Finally, BTIG Research boosted their price objective on Carlsmed from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, November 7th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $22.00.

Carlsmed Trading Up 3.1%

CARL stock opened at $13.11 on Friday. The business’s 50 day simple moving average is $13.51. Carlsmed has a 52-week low of $11.76 and a 52-week high of $16.20.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. Carlsmed has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CARL. Orbimed Advisors LLC acquired a new position in shares of Carlsmed during the third quarter valued at $16,772,000. Vanguard Group Inc. bought a new position in Carlsmed in the 3rd quarter valued at about $3,042,000. Teacher Retirement System of Texas acquired a new position in Carlsmed during the 3rd quarter valued at about $2,343,000. Russell Investments Group Ltd. bought a new stake in shares of Carlsmed during the 3rd quarter worth about $2,128,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Carlsmed in the 3rd quarter worth approximately $2,026,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).